1.
 The new initiative is focused on gene therapy. Pfizer operates a gene
therapy research facility at the Sanford complex.
 “The new facility will help advance Pfizer’s work in researching highly
specialized, potentially one-time gene therapy treatments that use custom-
made adeno-associated virus (AAV) vectors to deliver treatment effectively
to patients” according to Pfizer.
Pfizer to announce more jobs, investment at
Sanford, NC plant

2.
 Pfizer, the world’s largest drugmaker, plans to divest its off-patent drug
business and combine it with generic-drug maker Mylan.
 Under the agreement, which is structured as an all-stock deal, each Mylan
share would be converted into one share of the new company.
 Pfizer shareholders would own 57% of the combined new company and
Mylan shareholders would own 43%, Mylan said.
Pfizer will combine its off-patent drug business
with Mylan

3.
 Pfizer announced in mid-June that it would buy Array (ARRY) in a deal
worth a reported $10.6 billion.
Pfizer acquires Array BioPharma

4.
 The FDA has approved Pfizer’s rituximab biosimilar, Ruxience (rituximab-pvvr),
referencing Rituxan. The biosimilar was approved to treat non-Hodgkin lymphoma,
chronic lymphocytic leukemia, and granulomatosis with polyangiitis and
microscopic polyangiitis.
 The fact that the biosimilar was not approved for all indications of its reference, a
Pfizer representative told The Center for Biosimilars® in an email, is due to the fact
that “Genentech has exclusivity for rituximab in certain indications. Pfizer has
agreed to the terms of a global settlement,” but “specific terms and conditions of
the settlement are confidential.”
FDA Approves Pfizer's Rituximab Biosimilar,
Ruxience

5.
 Pfizer Inc said it acquired a 15 percent stake in Vivet Therapeutics, as well
as an exclusive option to fully acquire it, a deal that will give it access to
the French company’s experimental gene therapy for a rare genetic
disorder called Wilson disease.
 Pfizer has paid Vivet about $51 million upfront and may pay up to $635.8
million in clinical, regulatory milestone payments and to exercise the
option to buy the whole company.
Pfizer buys stake in French gene therapy firm
Vivet

6.
 The U.S. Food and Drug Administration approved Pfizer Inc’s oral drug,
tafamidis, to treat a rare and fatal heart disease called transthyretin
amyloid cardiomyopathy.
 Pfizer, which has touted tafamidis as a potential blockbuster product, set a
list price of $225,000 a year for the medicine, which would be sold under
the brand name Vyndaqel.
The U.S. Food and Drug Administration approved
Pfizer Inc’s oral drug, tafamidis

7.
 More than three years after snapping up Hospira, Pfizer has finally
decided that some of its manufacturing facilities in India are beyond
redemption.
 The U.S. pharma will shut down its long-troubled injectables facility in
Irungattukottai, India, as well as another site in Aurangabad, India, both of
which were folded into Pfizer through the $15 billion acquisition of Hospira
in 2015.
Pfizer will shut down its injectables facility in
Irungattukottai, India, as well as another site in
Aurangabad, India

8.
The Pfizer TURBO report has dozens of pages of customer insights
compiled to help you sell and market more effectively.
FORTUNE 500 TURBO REPORTS
844.DATABAHN
844.328.2224 ext. 707
info@databahn.com
www.databahn.com
We help sales reps and marketers eliminate costly research time and
uncover new sales pipeline opportunities.
Please visit www.databahn.com/page/turbo to download a TURBO Fortune
500 company profile report (PDF).
We also build custom deep dive Fortune 1000 company profile reports.
Please contact us if you need help.